Literature DB >> 27090936

Identification of IgE.

Kimishige Ishizaka1, Teruko Ishizaka2.   

Abstract

Progress in protein chemistry in the 1950s revealed that the biologic activities of proteins, such as hemoglobin and enzymes, are based on partial structures in the protein molecules. This principle suggested to us the possibility that the human antibodies responsible for induction of reaginic hypersensitivity reactions might have unique structures that are lacking in the antibody molecules involved in immunity and that the differences in the structures of human antibody molecules can be recognized by the immune systems of experimental animals. Our studies were based on the hypothesis that reaginic antibody activity is associated with a unique immunoglobulin isotype, which is now called IgE. As expected, identification of IgE facilitated the analysis of immunologic mechanisms of reaginic hypersensitivity. Subsequent studies revealed that IgE specifically bound to basophilic granulocytes and mast cells through the Fc portion of the molecules and that cross-linking of the cell-bound IgE antibody molecules by allergen induced the release of bioactive mediators, such as histamine and leukotrienes, which initiate allergic reactions.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IgE; reagin

Mesh:

Substances:

Year:  2016        PMID: 27090936     DOI: 10.1016/j.jaci.2015.12.1343

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

Review 1.  Human hyper-IgE syndrome: singular or plural?

Authors:  Qian Zhang; Bertrand Boisson; Vivien Béziat; Anne Puel; Jean-Laurent Casanova
Journal:  Mamm Genome       Date:  2018-08-09       Impact factor: 2.957

2.  Immunoglobulin E-an Innocent Bystander in Host Defense?

Authors:  Qian Zhang; Mikko R J Seppänen
Journal:  J Clin Immunol       Date:  2018-02-15       Impact factor: 8.317

Review 3.  From IgE to Omalizumab.

Authors:  Toshiaki Kawakami; Ulrich Blank
Journal:  J Immunol       Date:  2016-12-01       Impact factor: 5.422

4.  Receptor-destroying enzyme (RDE) from Vibrio cholerae modulates IgE activity and reduces the initiation of anaphylaxis.

Authors:  Tatsuya Yamazaki; Masanori Inui; Keiko Hiemori; Susumu Tomono; Makoto Itoh; Isao Ichimonji; Akina Nakashima; Hidekazu Takagi; Mrityunjoy Biswas; Kumi Izawa; Jiro Kitaura; Teruko Imai; Nobuo Sugiura; Hiroaki Tateno; Sachiko Akashi-Takamura
Journal:  J Biol Chem       Date:  2019-03-04       Impact factor: 5.157

Review 5.  Modeling asthma: Pitfalls, promises, and the road ahead.

Authors:  Helene F Rosenberg; Kirk M Druey
Journal:  J Leukoc Biol       Date:  2018-02-16       Impact factor: 4.962

6.  Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study.

Authors:  J Eckl-Dorna; R Fröschl; C Lupinek; R Kiss; P Gattinger; K Marth; R Campana; I Mittermann; K Blatt; P Valent; R Selb; A Mayer; K Gangl; I Steiner; J Gamper; T Perkmann; P Zieglmayer; P Gevaert; R Valenta; V Niederberger
Journal:  Allergy       Date:  2017-12-12       Impact factor: 13.146

Review 7.  The other side of the coin: IgE deficiency, a susceptibility factor for malignancy occurrence.

Authors:  Denisa Ferastraoaru; Galateja Jordakieva; Erika Jensen-Jarolim
Journal:  World Allergy Organ J       Date:  2021-02-06       Impact factor: 4.084

Review 8.  IgE in the Pathogenesis of SLE: From Pathogenic Role to Therapeutic Target.

Authors:  Yasmine Lamri; Nicolas Charles
Journal:  Antibodies (Basel)       Date:  2020-12-08

Review 9.  Omalizumab and IgE in the Control of Severe Allergic Asthma.

Authors:  Yasuhiro Gon; Shuichiro Maruoka; Kenji Mizumura
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

10.  The Fab fragment of anti-IgE Cε2 domain prevents allergic reactions through interacting with IgE-FcεRIα complex on rat mast cells.

Authors:  Takao Hirano; Akemi Koyanagi; Kaoru Kotoshiba; Yoichi Shinkai; Masataka Kasai; Tomoaki Ando; Ayako Kaitani; Ko Okumura; Jiro Kitaura
Journal:  Sci Rep       Date:  2018-09-24       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.